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OBJECTIVES This study assessed the role of angiotensin II type 1 (AT1) receptor antagonists on
inflammatory mechanisms involved in atherogenesis. Specific inflammatory markers included
solubilized tumor necrosis factor-alpha receptor II (sTNF-aRII), vascular cell adhesion
molecule-1 (VCAM-1) and superoxide. In addition, the AT1 receptor blocker irbesartan was
evaluated for its ability to suppress these markers in individuals with atherosclerosis.
BACKGROUND Mechanisms involved in the complex process of atherogenesis include alterations in the
inflammatory responses. The use of compounds that suppress these responses may reduce the
degree of damage seen in atherosclerosis.
METHODS With a cross-sectional study design, 33 normotensive patients with stable coronary artery
disease (CAD) were treated with irbesartan for a 24-week period. These patients were
compared against a control population with no known coronary atherosclerosis. Marker levels
were measured by enzyme-linked immunosorbent assay technique and lucigenin chemilumi-
nescence assay and statistically evaluated by two-way repeated measures analysis of variance.
RESULTS All patients with coronary artery disease had increased levels of inflammatory molecules over
those of control patients. Treatment with irbesartan in these patients significantly reduced
levels of inflammatory molecules measured. Soluble VCAM-1 levels were reduced by 36%;
soluble TNF-alpha levels were reduced by 54% and superoxide level decreased by 52%.
Maximal suppression of inflammatory markers by irbesartan therapy in patients with CAD
was seen at 12 weeks.
CONCLUSIONS The effect of irbesartan on each inflammatory marker is significant. Our results show that use
of irbesartan may retard the inflammatory process seen in premature forms of atherosclerosis.
(J Am Coll Cardiol 2001;37:440–4) © 2001 by the American College of Cardiology
Atherosclerosis is a pervasive condition responsible for more
than half of all mortality in the U.S. (1). Its impact has
reached epidemic proportions and has generated significant
research into the components that initiate and form athero-
sclerotic lesions. One such component involves an inflam-
matory process related to the oxidative modification of
low-density lipoproteins (ox-LDL) (2). In the presence of
ox-LDL, inflammatory markers such as vascular cell adhe-
sion molecule-1 (VCAM-1) and tumor necrosis factor-
alpha receptor II (sTNF-aRII) (3) are elevated. Studies by
Keidar et al. (4) imply that the use of compounds with
antioxidant properties, such as losartan, may be therapeutic
in the treatment of atherosclerosis by decreasing the oxida-
tion of LDL. These compounds appear to target the
oxidation of LDL and may reduce the impact of the
inflammatory process seen in atherogenesis.
Current treatment modalities are used to lower choles-
terol and LDL levels as well as control hypertension. The
association between hypertension and atherosclerosis has
not fully been established, but preliminary studies indicate a
causal relationship (5). Each class of antihypertensive med-
ications has a different effect on atherosclerotic lesions (5).
For example, alpha-blockers benefit atherosclerotic lesions
by changing the lipid profile (increasing high density li-
poproteins [HDL] and decreasing triglycerides) (6),
whereas angiotensin-converting enzyme inhibitors and cal-
cium channel blockers have potential antiatherogenic effects
at different points of the lesion development (7,8). Specific
beta-blockers, such as carvedilol, have been shown to
possess possible antioxidant properties and may prevent
LDL oxidation, thereby slowing the atherosclerotic process
(9).
Type 1-specific angiotensin receptor blockers are prom-
ising antihypertensive drugs, but there is little research on
their effect on atherosclerosis. The majority of research
concerning inhibitors of the angiotensin type 1 (AT1)
receptor has focused on their mechanism of action in
treating hypertension, which involves blocking the renin-
angiotensin system. This system regulates blood pressure
through salt and water homeostasis via vasoconstriction and
aldosterone secretion (10). Any imbalance in this system
results in elevated blood pressure. The major component
involved in the renin-angiotensin system is angiotensin II.
Angiotensin II acts by binding to plasma membrane recep-
tors, creating a cascade of cellular responses leading to an
increase in blood pressure (10). The discovery of nonpeptide
angiotensin II receptor antagonists, losartan being the
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prototype, led to the elucidation of angiotensin II receptor
subtypes 1 and 2 (AT1 and AT2)(11,12). The AT1 receptor
appears to play the major role in blood pressure mechanics
and is the target in the treatment of hypertension (13).
Initial clinical evidence has indicated that the use of angio-
tensin II receptor blockers is effective in treating hyperten-
sion (14). It also appears that the use of AT1 receptor
blockade increases AT2 receptor activity. This agonist effect
is postulated to work by increasing nitric oxide levels, which
may result in diminished cell proliferation and activation of
antioxidant properties (15). This mechanism may also be
influential in retarding the atherosclerotic process. Our
hypothesis is that inhibitors of the AT1 receptor suppress
the activity of the renin-angiotensin system in patients who
are susceptible to the inflammatory reactions that are critical
in the pathogenesis of atherosclerosis.
METHODS
Subjects. Thirty-three patients were enrolled in the study.
All study group subjects had documented coronary artery
disease (CAD) and had undergone coronary artery bypass
graft (CABG), percutaneous transluminal coronary angio-
plasty or both at least 12 months prior to the start of this
study. Those individuals who demonstrated a significant
stenosis of at least 50% of at least one main branch of the
coronary arteries were considered as having CAD (16).
Systolic blood pressure for all patients was ,150 mm Hg.
All patients were informed of the purpose of the study and
voluntarily consented to participate in accordance with
procedures established by the Human Studies Committee at
Emory University. Medical history of each patient indicated
no present or past history of diabetes mellitus or collagen
vascular disease. Patients were given irbesartan at 75 to
150 mg/day depending upon the level of blood pressure
measured. Patients with a systolic blood pressure of
#135 mm Hg were started on 75 mg of irbesartan per day,
whereas patients with a systolic blood pressure of
.135 mm Hg were started on 150 mg irbesartan per day.
No patients experienced hypotension during the study
period.
Blood sampling and laboratory determination. The study
spanned 24 weeks with serum samples collected at 0, 4, 12
and 24 weeks. Blood samples were drawn in seated position
from the antecubital vein. All samples were cooled with ice.
Serum was extracted by centrifugation at 3,000 g for 10 min.
Serum samples remained stored at 270°C until assays were
performed.
Serum vascular cell adhesion molecule-1 (sVCAM-1)
(ng/dl) was used as a representative circulating adhesion
molecule. Recent research has indicated that various adhe-
sion molecules may be specific to atherogenesis (17,18) with
serum VCAM-1 being a potential marker for atherosclero-
sis (19). Serum tumor necrosis factor-alpha receptor II
(TNF-aRII) (ng/dl) was measured as an indirect marker of
monocyte/macrophage stimulation (16). Serum levels of
VCAM and TNF-aRII were measured using a commer-
cially available enzyme-linked immunosorbent assay
(ELISA) technique (BioSound Technology, Chicago, Illi-
nois). Superoxide production has been associated with
vascular diseases such as atherosclerosis (20). Superoxide
levels were measured using the lucigenin chemilumines-
cence assay (21).
Statistical analysis. Statistical analysis was performed us-
ing analysis of variance. All analyses were tested as two-
sided and p values ,0.05 were considered statistically
significant.
RESULTS
Subject profile. Clinical parameters of all subjects are
presented in Table 1. Of the 33 patients, 17 were male and
16 female. Their ages ranged from 42 to 55 years in
the CAD group. Cholesterol levels ranged from 171 to
233 mg/dl (mean 5 206). Triglyceride levels ranged from
Abbreviations and Acronyms
AT1 5 angiotensin II type 1 receptor
AT2 5 angiotensin II type 2 receptor
CABG 5 coronary artery bypass graft
CAD 5 coronary artery disease
ESR 5 erythrocyte sedimentation rate
HDL 5 high density lipoproteins
ox-LDL 5 oxidized low density lipoproteins
sTNFa-IIR 5 soluble tumor necrosis factor-alpha
receptor type II
TNF-aRII 5 tumor necrosis factor-alpha receptor II
sVCAM 5 soluble vascular cell adhesion molecule
VCAM-1 5 vascular cell adhesion molecule-1
Table 1. Demographic Characteristics of Study Population and
Control Population
Control
(n 5 24)
Study Group
(CAD)
(n 5 33)
Male/female 12/12 17/16
Age range (yrs) 41–59 42–55
Body mass index (kg/m2) 26.6 (20–38) 27.0 (21–35)
Systolic blood pressure range
(mm Hg)
124–139 120–135
Diastolic blood pressure range
(mm Hg)
75–87 72–85
Leukocytes (nl21) 7.9 (4.5–11.1) 7.1 (4.2–10.4)
Total cholesterol (ng/dl) 209 (144–248) 206 (171–233)
Triglycerides (ng/dl) 125 (79–189) 142 (100–216)
Previous history of smoking 25% 32%*
History of myocardial
infarction
0 48%
Ejection fraction
.60% 100% 78%
55–40% 0 15%
39–20% 0 6%
,20% 0 0
*25% men, 39% women.
CAD 5 coronary artery disease.
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100 to 216 mg/dl (mean 5 142). Sixteen patients (48%) had
documented history of myocardial infarctions in the past.
Twenty-six patients (78%) had an ejection fraction of
.60%, with the rest of the subject population ranging
between 20% and 60% ejection fractions. None of the
patients fell below 20% ejection fraction. Body mass index
ranged from 21 to 35 (mean 5 27). All patients had normal
to borderline blood pressure, with no one above 135/85.
Eleven patients (32%) were smokers. All patients were on
antianginal therapy.
Analysis of blood pressure in patients with CAD treated
with irbesartan. Figure 1 displays the blood pressure
change in patients with CAD treated with irbesartan over
the study period. There was a decrease in systolic and
diastolic blood pressure measured at the four-week interval
of 6 mm Hg systolic and 4 mm Hg diastolic. Subsequent
measurements at 4, 12, and 24 weeks showed no change in
blood pressure after the decrease at the 4-week interval.
Analysis of serum levels of adhesion molecules and
markers. The data in Figure 2 show that serum levels of
soluble VCAM-1 were significantly increased at interval
0 weeks compared to corresponding levels in control pa-
tients (466.6 6 69.7 ng/dl vs. 331.6 6 39.5 ng/dl at
0 weeks). The graph also indicates serum VCAM-1 levels
decreased significantly in patients with CAD treated with
irbesartan as compared against control patients over the
24-week study interval (325.3 6 42.3 ng/dl vs. 466.6 6
69.7 ng/dl at 24 weeks). Serum VCAM levels remained
constant at 331.6 ng/dl in the control population through-
out the study interval. We studied the levels of sVCAM-1
in a separate group of patients with CAD that would have
met the inclusion criteria for the study but were not treated
with irbesartan (data not shown). No significant changes in
sVCAM-1 were observed after 24 to 26 weeks past the
collection of the initial samples, suggesting that irbesartan
alone was responsible for the reduction of sVCAM-1 in
patients with CAD.
Figure 3 shows a similar pattern for TNF-aRII levels.
Figure 1. Patients with premature CAD were placed on a daily dose of
irbesartan (75 mg daily if systolic blood pressure #135 mm Hg and 150 mg
daily if systolic blood pressure $135 mm Hg) for a 24-week period. Blood
pressure was monitored at 0, 4, 12 and 24-week intervals. The average
systolic and diastolic blood pressure for the group at each interval is noted.
} 5 systolic; n 5 diastolic.
Figure 2. Serum levels of soluble VCAM-1 (ng/dl) were measured in
subjects with known coronary artery disease (CAD) by enzyme-linked
immunosorbent assay technique. Diamonds represent the change in
sVCAM-1 levels over the 24-week study period at intervals of 0, 4, 12 and
24 weeks in patients with CAD treated with irbesartan. Squares represent
sVCAM-1 levels measured in control patients over the study period at the
same interval schedule. Values for CAD patient group represent mean 6
SD. * 5 value differs (p , 0.001) from the control group. # 5 value differs
(p , 0.001) from the CAD group before treatment with irbesartan. } 5
CAD; n 5 control.
Figure 3. Serum levels of TNFa-RII (ng/dl) were measured in subjects
with known coronary artery disease (CAD) by enzyme-linked immunosor-
bent assay technique. Diamonds represent the change in TNFa-RII levels
over the 24-week study period at intervals of 0, 4, 12 and 24 weeks in
patients with CAD treated with irbesartan. Squares represent TNFa-RII
levels measured in control patients over the study period at the same
interval schedule. Values for CAD patient group represent mean 6 SD.
* 5 value differs (p , 0.001) from the control group. # 5 value differs (p ,
0.001) from the CAD group before treatment with irbesartan. } 5 CAD;
n 5 control.
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The graph indicates that patients with CAD had an
elevated level of TNF-a RII at the zero time interval as
compared with their control counterparts (319.15 6
30.2 ng/dl vs. 221 6 63.5 ng/dl). The graph also shows that
treatment with irbesartan in the population of patients with
CAD significantly reduced TNF-aRII levels to those of the
control population (227 6 27.9 ng/dl vs. 221 6 63.5 ng/dl
at 24 weeks). Marker levels of TNF-aRII in control
patients remained constant at 221 ng/dl for the length of the
study.
Figure 4 displays the change in superoxide levels in
patients with CAD as compared to control patients. Initial
values indicate that superoxide levels were significantly
greater in patients with CAD as compared to control
(231.2 6 43.7 ng/mg vs. 143.6 6 40.1 ng/mg at 0 weeks).
Treatment with irbesartan decreased superoxide levels to
that of control patients in patients with CAD (158 6
25.9 ng/mg vs. 143.6 6 40.1 ng/mg at 24 weeks).
Over the 24-week period, serum VCAM-1 levels de-
creased by 36% in the irbesartan-treated patient group.
Serum TNF-aRII levels decreased by 54% and superoxide
levels fell 52% in the irbesartan-treated group over the study
period. No change in inflammatory markers was noted in
any of the control subjects for the span of the study. We
studied other serum markers that are associated with in-
flammation, including total C-reactive protein and erythro-
cyte sedimentation rate (ESR). We observed that there was
no difference in these markers between the control and
CAD group (data not shown); moreover, treatment with
irbesartan did not affect C-reactive protein or ESR in the
CAD group.
DISCUSSION
This study focused on the effect of the AT1 antagonist
irbesartan on subjects who develop early forms of athero-
sclerosis. We demonstrated that this drug reduces circulat-
ing inflammatory markers associated with CAD. Serum
VCAM, TNF-aRII and superoxide were elevated to be-
tween 40% and 100% higher than controls. Irbesartan
decreased the amount of inflammatory molecules to below
levels of control.
Adhesion molecules as markers for CAD. The markers
measured in our study were chosen for specific reasons.
Recent studies by Peter et al. (19) and DeCaterina et al. (22)
indicate that soluble VCAM levels may be considered a
marker for quantifying atherosclerosis, particularly in the
early stages of the disease process. Tumor necrosis factor-
alpha and its receptor subtypes (RI and RII) have been
considered as potential markers for atherosclerosis (3).
Tumor necrosis factor-alpha RII is the stable receptor
subtype for TNF-a and appears to be associated with CAD
(16). Because of its stability in comparison with TNF-a and
TNF-a-RI, TNF-a-RII was considered an ideal investiga-
tive marker to use in this study. Our study indicates that
TNF-a-RII levels are increased to a significant degree in
patients with early atherosclerosis. Superoxide levels have
been associated with hypercholesterolemia (23) and endo-
thelial dysfunction (20). These properties result in the
oxidation of LDL. Oxidized low density lipoprotein then
damages the vascular endothelium and promotes the ath-
erosclerotic lesion (24). In our study, we found that patients
with premature CAD had elevated levels of superoxide.
This result supports the in vitro studies done by Miller et al.
(25) and indicates that superoxide levels are increased
secondary to the oxidative environment created by elevated
lipid levels.
Irbesartan decreases inflammatory marker levels in pre-
mature patients with CAD, which may operate via anti-
oxidant-sensitive mechanisms. Much of the research
literature concerning irbesartan involves its efficacy in the
treatment of hypertension. The present study addresses the
potential effects of AT1 receptor blockers on the inflamma-
tory markers of atherosclerosis. Our study indicates that
irbesartan at therapeutic doses can reduce the inflammatory
reaction to atherosclerosis without significant hypotension
in normotensive patients with CAD. The mechanism of
this reduction is unclear but may involve the inhibition of
NAD(P)H-dependent oxidases. Warnholtz et al. (23) pro-
posed that AT1 receptor activation by angiotensin II in-
creases the amount of superoxide. The increase in superox-
ide results in LDL oxidation and inhibition of nitric oxide
and prostacyclin (26). All of these components ultimately
result in the endothelial dysfunction seen in the atheroscle-
rotic process. Blocking the AT1 receptor decreases the
detrimental effect of superoxide on the vasculature. Kurz et
al. (27) demonstrated that losartan, the angiotensin receptor
blocker prototype, produced this effect through AT1 block-
Figure 4. Serum levels of superoxide (ng/mg) were measured in subjects
with known coronary artery disease (CAD) by the lucigenin chemilumi-
nescence assay. Diamonds represent the change in TNFa-RII levels over
the 24-week study period at intervals of 0, 4, 12 and 24 weeks in patients
with CAD treated with irbesartan. Squares represent superoxide levels
measured in control patients over the study period at the same interval
schedule. Values for CAD patient group represent mean 6 SD. * 5 value
differs (p , 0.01) from the control group. # 5 value differs (p , 0.01) from
the CAD group before treatment with irbesartan. } 5 CAD; n 5 control.
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ade. Our study indicates that irbesartan also has a significant
effect on reducing superoxide production and probably uses
a similar mechanism of action.
The issue of using patients with a past history of some
intervention, such as CABG or coronary angioplasty, may
indicate a potential source for the elevated marker levels.
This concern was addressed in the study done by Porsche et
al. (16), which found no differences in the marker levels they
examined in patients with CABG and those patients who
received an interventional procedure. Another concern in-
volves the specificity of inflammatory markers in regards to
atherosclerosis. Only a handful of markers have been stud-
ied in any detail. The markers used in this study represent
inflammatory molecules found in atherosclerosis as deter-
mined by other studies (22–24,28).
Our results indicate two conclusions. First, the study
demonstrates that patients with a premature form of coro-
nary artery disease have significantly increased levels of
VCAM-1, TNF-a-RII and superoxide as compared to
their control counterparts. Second, irbesartan significantly
reduces the levels of these molecules in patients with CAD.
The first conclusion shows that our results mirror work
done by other researchers (19,29) establishing an inflamma-
tory process in atherogenesis. The second conclusion indi-
cates that irbesartan, possibly through its mechanism of
action, reduces the inflammatory response seen in athero-
sclerosis. These findings imply that the use of irbesartan in
low doses may retard the inflammatory component of the
atherosclerotic process without affecting blood pressure.
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